Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Stool Test Could Better Detect COVID-19 than Traditional Nose Swabs Due to Prolonged Gut Viral Infection

By HospiMedica International staff writers
Posted on 08 Sep 2020
Researchers have found for the first time that COVID-19 patients have active and prolonged gut viral infection, suggesting that stool tests could be more safe, accurate and non-invasive than traditional nose swabs in detecting coronavirus.

Researchers from the Faculty of Medicine of The Chinese University of Hong Kong (Sha Tin District, Hong Kong) found that COVID-19 patients have active and prolonged gut viral infection, even in the absence of gastrointestinal (GI) symptoms. More...
After respiratory clearance of coronavirus, the activity of viral infection and replication still persists in the gut. To better understand the activity and infectivity of COVID-19 virus in the GI tract during the disease’s course, the researchers investigated the stool samples of 15 COVID-19 patients in Hong Kong. The researchers found that there was active gut viral infection in seven patients even in the absence of GI symptoms. Three patients continued to display active viral infection up to six days after clearance of the virus from their respiratory samples. The researchers also found that gut microbiota of patients with high SARS-CoV-2 infectivity were characterized by enrichment of pathogens and loss of “good” bacteria that are capable of producing short-chain fatty acid.

Earlier studies have found that the COVID-19 virus was detectable in the stool samples of all patients, regardless of the degree of illness. The researchers undertook screening of more than 128 stool samples of Hong Kong airport arrivals that revealed six children with confirmed COVID-19 infection and a detection rate of 0.28%. The researchers believe that stool screening test can help identify asymptomatic people carrying the COVID-19 virus as early as possible in order to stop its spread in the community.

“The viral load in the stool of infant and children is many times higher than that in adults, and could be equivalent to that of adult respiratory samples,” said Professor Paul Kay Sheung CHAN, Chairman of the Department of Microbiology and Associate Director of the Centre for Gut Microbiota Research. “The activity of viral infection and replication also persist longer in the guts of infant and children. Stool specimens are more convenient, safe and non-invasive to collect in the paediatric population and can give accurate results. This makes stool test a better option for COVID-19 screening in babies, young children and those whose respiratory samples are difficult to collect.”

Related Links:
The Chinese University of Hong Kong


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.